Search

Abstarct: Aim: Recently, increasing evidence showed that small-for-size syndrome (SFSS) is a multifactorial disease which is precipitated by various perioperative factors other than graft size. We conducted the current work to evaluate perioperative effectors, which can increase the risk of SFSS following adult living-donor liver transplantation (LDLT). Methods: This is a retrospective study on 110 adult cirrhotic cases (mean age of 48.4 ± 6.9 years old) who underwent adult LDLT. Most cases were males (89%). Cases were categorized into two groups based on the occurrence of SFSS. The groups were compared regarding preoperative (gender, age, comorbidities, baseline investigations), intraoperative (mean blood pressure and glucose; mean operation time; number of packed red cells, plasma, platelets, and cryoprecipitate units; time of cold and warm ischemia, and anhepatic phase; preclamping and post-reperfusion portal pressures), and postoperative factors (relevant investigations, hospital stay). Results: Postoperatively, 23 patients developed SFSS (20.9%). SFSS group had significantly lower preoperative graft recipient weight ratio (GRWR) (0.76 ± 0.1% versus 1.03 ± 0.15, respectively; p

Graphical abstract, This study investigated the elimination of Cr(VI) from aqueous solution utilizing a composite from magnetic nanoparticles (Fe3O4) capped with cetyltrimethylammonium bromide (CTAB). The structure of the prepared composite system was examined by Fourier Transform Infra Red Spectroscopy (FTIR), X-ray Diffractometry (XRD), and Transmission Electron Microscopy (TEM). Separation of the Fe3O4/CTAB composite from the wastewater can be achieved by application of an external magnetic field. Factors affecting the Cr(VI) expulsion from wastewater such as pH, competing ions, the dosage level of the nanoparticles, and contact time were studied. The results indicated that the maximum efficiency of the present system for removal of Cr(VI) (95.77%) was in acidic conditions (pH 4), contact time 12 h, and composite dosage of 12 mg/mL. The used Cr(VI) concentration was 100 mg/L. Considering results, the Fe3O4/CTAB system showed a high capability and selectivity for the treatment of water sullied with Cr(VI). This can recede the mutagenic and carcinogenic health risk caused by Cr(VI) water tainting.